Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
Status:
Completed
Trial end date:
2019-03-15
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine whether post-transplant consolidation with azacitidine
combined with donor lymphocyte infusion (DLI) is a safe and effective approach for the
prevention of relapse in pediatric and young adult patients with hematologic malignancies who
have undergone hematopoietic stem cell transplantation (HSCT).
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Children’s Hospital of Orange County Hellman Foundation Johns Hopkins All Children's Hospital Lucile Packard Children's Hospital